1.Study on present situation and safety of TCM injection
International Journal of Traditional Chinese Medicine 2012;34(3):227-228
Boosted in the rapid action,Traditional Chinese medical injection (TCMI) played an important role in the treatment of severe cases.In recent years,the safety of TCMI caused extensive concern of the domestic pharmaceutical indnstry.The clinical application of TCMI was analyzed in this paper to expound the existing security problem and to make reasonable suggestions for the evaluation.
5.The effect of different analgesia methods on postoperative cellular immune function in patients with radical resection of lung cancer
Chinese Journal of Postgraduates of Medicine 2013;(18):32-35
Objective To study the effect of different analgesia methods on postoperative cellular immune function in patients with radical resection of lung cancer.Methods Fifty patients undergoing selective radical resection of lung cancer were randomly divided into two groups.Group A (25 patients) was given morphine patient-controlled epidural analgesia(PCEA) and group B (25 patients) was given preemptive analgesia with parecoxib combined with morphine PCEA.T-lymphocyte subsets (CD4+,CD8+)and natural killer cell (NK cell) were measured by flow cytometry at preanesthesia,2 h intraoperative,24,48 h postoperative.Results The level of CD4+,CD8+ and NK cell in two groups at preanesthesia had no significant difference (P >0.05).The level of CD4+ and CD4+/CD8+ in two groups at 2 h intraoperative,24,48 h postoperative were significantly lower compared with preanesthesia (group A:CD4+:0.252 ± 0.035,0.227 ±0.025,0.248 ± 0.028 vs.0.310 ± 0.032,CD4+/CD8+:1.2 ± 0.1,1.0 ± 0.1,1.1 ± 0.2 vs.1.5 ± 0.2;group B:CD4+:0.265 ± 0.033,0.263 ± 0.028,0.264 ± 0.031 vs.0.312 ± 0.035,CD4+/CD8+:1.3 ± 0.2,1.2 ± 0.1,1.2 ± 0.1 vs.1.4 ± 0.1)(P < 0.05).Compared with group A,the range of descend of CD4+ and CD4+/CD8+ in group B was significantly less at 24,48 h postoperative (P < 0.05).The level of NK cell in two groups at 24,48 h postoperative was significantly lower than preanesthesia(O.112 + 0.019,0.113 + 0.016 vs.0.126 + 0.019 and 0.117 +0.016,0.120 +0.018 vs.0.127 + 0.021) (P <0.05).The level of NK cell in group B at 24,48 h postoperative was significantly higher than that in group A (P < 0.05).Conclusion Parecoxib sodium preemptive analgesia combined with morphine PCEA may reduce immune depress in tumor palients by lowering the range of descend of CD4+ and NK cell.
6.Treatment progress on castration-resistant prostate cancer
Qing WANG ; Jun DU ; Qing YANG
Chinese Journal of Clinical Oncology 2016;43(17):766-769
Castration-resistant prostate cancer is a fatal disease with rapid progress. This malignancy usually presents with metastasis and poor prognosis. This type of disease also often causes 100%mortality, of which the median survival time is less than 20 months. Thus, treatment of castration-resistant prostate cancer remains challenging, and the underlying mechanisms of this cancer have yet to be identified. Several new therapies for castration-resistant prostate cancer have been proposed, such as androgen receptor antago-nists, immunotherapeutic drugs, taxanes, antiangiogenic agents, radionuclides, and bone-targeting drugs. These therapies can im-prove the survival time of patients. The advances in the treatment of castration-resistant prostate cancer are briefly reviewed in this ar-ticle.
7.Case reports of two children with neurofibromatosis type 1
China Tropical Medicine 2023;23(6):672-
Abstract: Objective To report the clinical characteristics and genetic test results of two children with neurofibromatosis type 1 (NF1), and to provide reference for the comprehensive diagnosis-treatment and follow-up plans of NF1 patients based on the existing diagnosis and treatment progress of NF1. Methods Two children with NF1 admitted to the Department of Children's Medicine, Haikou people's Hospital in May and June 2022 were selected to analyze the clinical data of their clinical manifestations, laboratory examination, genetic test results, diagnosis and treatment and follow-up retrospectively. Results Two children had typical clinical manifestations, such as café-au-lait spots, axillary freckles, intraocular iris hamartoma. Venous blood was collected from case 1 and his parents for NF gene test, and a new mutation of c.4084C>T in the NF1 gene was found, and their parents did not have the pathogenic gene; the venous blood of the children in case 2 was tested for whole-exome gene analysis, and a heterozygous nonsense variant c.910C>T:p.R304 on the NF1 gene was found, , which was verified by Sanger sequencing to be inherited from his mother, his mother has café-au-lait spots and brain glioma, and has undergone surgery to remove the brain glioma, but has not undergone chemoradiotherapy or targeted therapy. No neurological malignancies were detected in either of the two children at follow-up until July 2022. Conclusions The clinical manifestations of NF1 are relatively typical, genetic testing is conducive to determine its classification, and regular follow-up review can help to detect and treat malignant tumors early, thus improving the patient's quality of life.
9.Value of immunohistochemistry in diagnosis and differential diagnosis of ovarian tumors.
Chinese Journal of Pathology 2009;38(4):280-284
Adenocarcinoma, Mucinous
;
metabolism
;
pathology
;
Calbindin 2
;
Carcinoma, Endometrioid
;
metabolism
;
pathology
;
Diagnosis, Differential
;
Female
;
Humans
;
Immunohistochemistry
;
methods
;
Inhibins
;
metabolism
;
Keratin-7
;
metabolism
;
Mucin-1
;
metabolism
;
Ovarian Neoplasms
;
metabolism
;
pathology
;
S100 Calcium Binding Protein G
;
metabolism
;
Sex Cord-Gonadal Stromal Tumors
;
metabolism
;
pathology
10.Advances in the Research of Long Life Recombinant Protein Drug
Nan QI ; Qing-Jun MA ;
China Biotechnology 2006;0(02):-
The recombinant protein drug usually has a short half-life after intravenous (IV) or subcutaneous (SC) administration. The methods of prolonging the half-life of recombinant protein drug in common use are mainly based on three principles: 1 Amplifying the molecule weight of protein drug; 2 Making use of drug balance in the blood; 3 Reducing Immunogenicity. Three methods were focused on: Analog construction, PEGylation and Albumin fusion technology. The characteristics, half-life and immunogenicity problem of their products in the market and under development are summarized.